| Followers | 843 |
| Posts | 123050 |
| Boards Moderated | 9 |
| Alias Born | 09/05/2002 |
Friday, March 27, 2009 12:42:47 AM
Re: Will Copaxone will regulated as a biologic? The key word in your post is full, and this is where I respectfully disagree.
I concur that some clinical testing for generic Copaxone is likely, but I highly doubt that it will need to be a full clinical program that starts from square one and is unable to rely in part on the branded Copaxone dossier.
If what you assert were what the FDA actually wanted, the FDA would very clearly not have accepted the Copaxone ANDA for review—they would instead have requested that the sponsors submit a regular NDA.
I don't believe the FDA will treat this other than a biologic drug - meaning full clinical trials to demonstrate safety and efficacy will be required.
I concur that some clinical testing for generic Copaxone is likely, but I highly doubt that it will need to be a full clinical program that starts from square one and is unable to rely in part on the branded Copaxone dossier.
If what you assert were what the FDA actually wanted, the FDA would very clearly not have accepted the Copaxone ANDA for review—they would instead have requested that the sponsors submit a regular NDA.
Recent TEVA News
- Teva to Present at the Goldman Sachs Global Healthcare Conference • GlobeNewswire Inc. • 06/01/2026 08:30:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 06/01/2026 08:16:53 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 06/01/2026 08:15:03 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 06/01/2026 08:13:45 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 06/01/2026 08:11:33 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 06/01/2026 08:09:58 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 06/01/2026 08:08:27 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 06/01/2026 08:06:34 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 06/01/2026 08:03:55 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 06/01/2026 08:02:23 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/28/2026 08:05:43 PM
- The European Medicines Agency Accepts Teva’s Marketing Authorization Application for Olanzapine Long-Acting Injectable (TEV-‘749) for the Treatment of Schizophrenia in Adults • GlobeNewswire Inc. • 05/21/2026 04:30:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/18/2026 08:02:42 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/18/2026 08:00:48 PM
- Fitch Upgrades Teva to Investment Grade Amid Pivot to Growth Execution • GlobeNewswire Inc. • 05/18/2026 12:30:00 PM
- Teva Study Finds Only 23% of Younger Adults with Mood Disorders and Tardive Dyskinesia (TD) Symptoms Are Formally Diagnosed with TD Despite Widespread Impact • GlobeNewswire Inc. • 05/18/2026 12:00:00 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 05/14/2026 08:02:02 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 05/14/2026 07:59:51 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/07/2026 08:03:44 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/07/2026 08:01:55 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 05/05/2026 08:00:07 PM
- Teva to Present at the BofA Securities Health Care Conference • GlobeNewswire Inc. • 05/04/2026 08:30:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/04/2026 08:02:22 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/04/2026 08:00:53 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 05/04/2026 12:12:51 PM

